title: [Prognostic importance of ambulatory arterial pressure monitoring in France. Initial results of the OCTAVE II study. OCTAVE II Research Group].
abstract: BACKGROUND
  Ambulatory blood pressure measurement (ABPM) is commonly used in clinical practice, whereas its added value to the management of hypertension is not definitely documented.
  
  
  OBJECTIVE
  The OCTAVE II study was launched in 1991 to explore the prognostic value of ABPM, compared to that of the gold standard, the clinical blood pressure measurement.
  
  
  METHODS
  Two hundred and six French cardiologists recruited 3569 participants over 18 years of age, provided they deemed ABPM was useful (mean age of 56 years, 52% of men, 65% already treated by antihypertensive drugs). The prognostic value of various blood pressure measurements, systolic or diastolic, clinical or ambulatory (diurnal, nocturnal or during 24 hours), has been assessed in multivariate models adjusted on the baseline characteristics associated with risk. The outcome was the occurrence of a major cardiovascular event, including stroke, myocardial infarction and cardiovascular death.
  
  
  RESULTS
  After an average follow-up of five years, cardiovascular morbidity was known for 85% of the participants, and their vital status for 91%. On the whole population, the best prognostic indicators were systolic blood pressure compared with diastolic, ABPM compared with clinical blood pressure measurements, and nocturnal ABPM compared with diurnal ABPM. In the untreated participants at baseline, cardiovascular risk regularly increased among the four groups: normotensives, white-coat hypertensives, dippers, non-dippers. Between the extreme categories, the cardiovascular event rate was multiplied by 6.5.
  
  
  CONCLUSIONS
  In this French population, ABPM and most of all its nocturnal component, was better correlated with cardiovascular prognosis. It remains to assess: 1) the general value of our findings, 2) the respective values of self blood pressure measurement versus ABPM, and 3) whether ABPM allows a better risk prevention.
authors.affiliation: EA 643, service de pharmacologie clinique, faculté RTH Laënnec, Lyon.
authors.forename: F
authors.initials: F
authors.lastname: Gueyffier
authors.forename: C
authors.initials: C
authors.lastname: Cornu
authors.forename: N
authors.initials: N
authors.lastname: Bossard
authors.forename: C
authors.initials: C
authors.lastname: Mercier
authors.forename: P
authors.initials: P
authors.lastname: Poncelet
authors.forename: A
authors.initials: A
authors.lastname: Sebaoun
authors.forename: G
authors.initials: G
authors.lastname: Jullien
authors.forename: C
authors.initials: C
authors.lastname: Aviérinos
authors.forename: J Y
authors.initials: JY
authors.lastname: Fraboulet
authors.forename: J P
authors.initials: JP
authors.lastname: Boissel
mesh_terms: D000328:Adult; D018660:Blood Pressure Monitoring, Ambulatory; D005260:Female; D005602:France; D006801:Humans; D006973:Hypertension / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D016896:Treatment Outcome